Compare ETON & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | CLVT |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2018 | 2020 |
| Metric | ETON | CLVT |
|---|---|---|
| Price | $55.35 | $1.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $71.00 | $2.97 |
| AVG Volume (30 Days) | 487.3K | ★ 3.9M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.75 |
| EPS | ★ 0.41 | N/A |
| Revenue | $79,950,000.00 | ★ $974,345,000.00 |
| Revenue This Year | $88.01 | N/A |
| Revenue Next Year | $49.11 | N/A |
| P/E Ratio | $133.54 | ★ N/A |
| Revenue Growth | ★ 104.94 | 0.61 |
| 52 Week Low | $14.27 | $1.42 |
| 52 Week High | $66.37 | $3.87 |
| Indicator | ETON | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 38.79 |
| Support Level | $53.60 | N/A |
| Resistance Level | $60.60 | $1.97 |
| Average True Range (ATR) | 3.45 | 0.09 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 54.78 | 32.71 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.